Notification of delay of decision on melatonin funding proposal
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund melatonin 2 mg modified-release tablets (Circadin) from 1 July 2014 for secondary insomnia in children and adolescents with neurodevelopmental disorders.
Consultation on this proposal has now closed. Some significant issues were raised in consultation responses, and we require additional time to consider them before a decision can be made on the proposal.
This delay will mean that a decision will not be made in time for 1 July 2014 funding changes. We do not currently have a firm timeframe for a decision to be made on this proposal but the decision will likely be made, and subsequently notified, within the next two months.
If you have any questions about this notification, please contact Geraldine MacGibbon, Senior Therapeutic Group Manager, by email at email@example.com.